Pejo Ervin, Zhou Xiaojuan, Husain S Shaukat, Raines Douglas E
From the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Anesthesiology. 2016 Nov;125(5):943-951. doi: 10.1097/ALN.0000000000001304.
Etomidate potently suppresses adrenocortical steroid synthesis with potentially deleterious consequences by binding to 11β-hydroxylase and inhibiting its function. The authors hypothesized that other sedative-hypnotics currently in clinical use or under development (or their metabolites) might bind to the same site at clinically relevant concentrations. The authors tested this hypothesis by defining etomidate's affinity for this site and the potencies with which other sedative-hypnotics (and their metabolites) inhibit etomidate binding.
H-etomidate's binding to adrenal membranes from Sprague-Dawley rats was characterized with a filtration assay, and its dissociation constant was defined using saturation and homologous ligand competition approaches. Half-inhibitory concentrations of sedative-hypnotics and metabolites were determined from the reduction in specific H-etomidate binding measured in the presence of ranging sedative-hypnotic and metabolite concentrations.
Saturation and homologous competition studies yielded H-etomidate dissociation constants of 40 and 21 nM, respectively. Half-inhibitory concentrations of etomidate and cyclopropyl methoxycarbonyl metomidate (CPMM) differed significantly (26 vs. 143 nM, respectively; P < 0.001), and those of the carboxylic acid (CA) metabolites etomidate-CA and CPMM-CA were greater than or equal to 1,000× higher than their respective parent hypnotics. The half-inhibitory concentration of dexmedetomidine was 2.2 µM, whereas those of carboetomidate, ketamine, and propofol were greater than or equal to 50 µM.
Etomidate's in vitro dissociation constant for 11β-hydroxylase closely approximates its in vivo adrenocortical half-inhibitory concentration. CPMM produces less adrenocortical suppression than etomidate not only because it is metabolized faster but also because it binds to 11β-hydroxylase with lower affinity. Other sedative-hypnotics and metabolites bind to 11β-hydroxylase and inhibit etomidate binding only at suprahypnotic concentrations.
依托咪酯通过与11β-羟化酶结合并抑制其功能,可有效抑制肾上腺皮质类固醇合成,可能产生有害后果。作者推测,目前临床使用或正在研发的其他镇静催眠药(或其代谢物)在临床相关浓度下可能会结合到同一部位。作者通过确定依托咪酯对该部位的亲和力以及其他镇静催眠药(及其代谢物)抑制依托咪酯结合的效力来验证这一假设。
采用过滤分析法对H-依托咪酯与Sprague-Dawley大鼠肾上腺膜的结合进行表征,并使用饱和法和同源配体竞争法确定其解离常数。通过在不同浓度的镇静催眠药和代谢物存在下测量特异性H-依托咪酯结合的减少量,来确定镇静催眠药和代谢物的半数抑制浓度。
饱和研究和同源竞争研究得出H-依托咪酯的解离常数分别为40和21 nM。依托咪酯和环丙基甲氧基羰基美托咪酯(CPMM)的半数抑制浓度差异显著(分别为26和143 nM;P < 0.001),羧酸(CA)代谢物依托咪酯-CA和CPMM-CA的半数抑制浓度比其各自的母体催眠药高1000倍以上。右美托咪定的半数抑制浓度为2.2 μM,而卡波依托咪酯、氯胺酮和丙泊酚的半数抑制浓度大于或等于50 μM。
依托咪酯对11β-羟化酶的体外解离常数与其体内肾上腺皮质半数抑制浓度密切接近。CPMM对肾上腺皮质的抑制作用比依托咪酯小,这不仅是因为它代谢更快,还因为它与11β-羟化酶的结合亲和力较低。其他镇静催眠药和代谢物仅在超催眠浓度下才会结合到11β-羟化酶并抑制依托咪酯结合。